Background: The vermilion border of the lower lip is a frequent location of squamous cell carcinoma (SCC), but it is very rarely mentioned within the published series of basal cell carcinomas (BCCs). Objective: We present 6 cases of BCC involving either mainly or exclusively the vermilion border of a lip. Methods: We reviewed from our files all the cases of BCC diagnosed in a period of 11 years. Results: A number of 3,477 BCCs were histologically diagnosed in that period; 2,872 (82.6%) of them were located on the head, and 66 (2.3%) of the latter (1.9% of all BCCs) were on the lips. In 6 cases, the neoplasm involved either mainly or exclusively the vermilion border of either the lower (5 cases) or the upper (1 case) lip. Conclusion: Not every carcinoma of the vermilion border of the lip is a SCC.

1.
Epstein JH: Photocarcinogenesis, skin cancer and aging. J Am Acad Dermatol 1983;9:487–502.
2.
Nishimura M, Hory Y: Adamantoid basal cell carcinoma: An ultrastructural study. Arch Pathol Lab Med 1991;115:624–626.
3.
Rahabari H, Meheregan A: Basal cell epitheliomas in usual and unusual sites. J Cutan Pathol 1979;6:425–431.
4.
Kopf AW: Computer analysis of 3,531 carcinomas of the skin. J Dermatol 1979;6:267–282.
5.
Roenigk RK, Ratz JL, Bilin PL, et al: Trends in the presentation and treatment of basal cell carcinomas. J Dermatol Surg Oncol 1986;12:860–865.
6.
Roberts DL: Incidence of non-melanoma skin cancer in West Glamorgan, South Wales. Br J Dermatol 1990;122:399–403.
7.
Marrón J, Martínez GJ, Vives JM, et al: Epidemiología de los epiteliomas cutáneo-mucosos en la comunidad de Aragón. Actas Dermosifiliogr 1992;83:153–159.
8.
Zubiri A, Berino F, Moral A, et al: Estadística de los cánceres cutáneos epiteliales en los países europeos de lengua latina. Actas Dermosifiliogr 1981;72:241–250.
9.
Coebergh JW, Neumann HA, Wrints LW, et al: Trends in the incidence of non-melanoma skin cancer in the SE Netherlands 1975–1988: A registry based study. Br J Dermatol 1991;125:353–359.
10.
Alcalaya BB, Falco AP, Jordan MP: Correlacíon anatomo-clínica de 600 casos de epitelioma basocelular. Actas Dermosifiliogr 1990;81:255–261.
11.
Hyman AB, Barsky AJ: Basal cell epithelioma of the palm. Arch Dermatol 1965;92:571–573.
12.
Berger RA, Auerbach R, Orentrich N: Basal cell epithelioma of the sole. Arch Dermatol 1966;94:317–319.
13.
Golitz LE, Norris DA, Luekens CA Jr, et al: Nevoid basal cell carcinoma syndrome. Multiple basal cell carcinomas of the palm after radiation therapy. Arch Dermatol 1980;166:1159–1163.
14.
Robins P, Rabinovitz HS, Riger D: Basal-cell carcinoma on covered or unusual sites of the body. J Dermatol Surg Oncol 1981;7:803–806.
15.
Feal C, Porras JI, Fernández Buezo G, Martínez López R, Herrera J: Carcinoma basocelular de la palma. Actas Dermosifiliogr 1998;89:52–55.
16.
Brody I: Contribution to the histogenesis of basal cell carcinoma. J Ultrastruct Res 1970;33:60–79.
17.
Miles AEW: Sebaceous glands in the lips and cheek mucosa of man. Br Dent J 1958;105:235.
18.
Steffen C, Ackerman AB: Neoplasms with Sebaceous Differentiation. Philadelpiha, Lea & Febiger, 1994, pp 71–86.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.